Prostate cancer diagnosis: should patients with prostate specific antigen >10 ng/ml have stratified prostate biopsy protocols?
|
|
- Gabriella Bryant
- 6 years ago
- Views:
Transcription
1 Cancer Detection and Prevention 32 (2009) Prostate cancer diagnosis: should patients with prostate specific antigen >0 ng/ml have stratified prostate biopsy protocols? Joe Philip MRCSI a, *, Ramaswamy Manikandan FRCS (Urol.) b, Pradip Javlé FRCS (Urol.) a, Christopher S. Foster FRCPath., PhD c a Department of Urology, Leighton Hospital, Crewe, Cheshire, CW 4QJ UK b Department of Urology, School of Cancer Studies, University of Liverpool, Duncan Building, Daulby Street, Liverpool, L69 3GA UK c Division of Pathology, School of Cancer Studies, University of Liverpool, Duncan Building, Daulby Street, Liverpool, L69 3GA UK Accepted 20 December 2008 Abstract Background: Trans-rectal ultrasound (TRUS) guided systematic prostate biopsy is a standard tool in prostate cancer (CaP) diagnosis. Extended biopsy techniques using 0 2 cores are the norm. Controversy exists on extended TRUS biopsy in men with PSA >0 ng/ml. We evaluated cancer detection rates on an individual core basis, to stratify prostate biopsy protocols based on PSA levels. Patients and methods: Over a five-year period, 036 patients underwent TRUS guided prostate biopsy for raised serum PSA (>2.5 ng/ml). 436 patients had PSA >0 ng/ml. Patients with PSA <50 ng/ml underwent a 2-core TRUS guided prostate biopsy including six peripheral biopsies. The six peripheral biopsies were directed laterally towards the base, mid-zone and apices. Remainder were standard para-sagittal sextant biopsies. Patients were stratified into three groups (PSA 0 20 ng/ml, ng/ml and >50 ng/ml). Results: Mean age of 436 patients with PSA >0 ng/ml was 70.3years. 270 (62%) men had cancer. Cancer detection rates for different PSA levels were 46% (0 20 ng/ml), 76% (20 50 ng/ml) and 93% (>50 ng/ml). Higher PSA levels and advanced clinical stage were associated with increased cancer detection rates. All patients with clinical T3 and T4 disease had biopsy diagnosed CaP. Conclusion: TRUS guided prostate biopsy in patients with PSA >0 ng/ml did not require 2 cores to diagnose CaP. CaP diagnosis required 8 cores in men with PSA 0 20 ng/ml. These cores were right and left peripheral basal and apical, and right and left para-sagittal basal and apical biopsy. Only 6 cores were necessary to diagnose CaP in men with PSA >20 ng/ml which were right and left peripheral basal and apical, and para-sagittal apical biopsies. We suggest limited TRUS prostate biopsy protocols for men with PSA >0 ng/ml. # 2008 Elsevier Ltd. All rights reserved. Keywords: Prostate cancer; PSA; Prostate biopsy; Limited biopsy protocols. Introduction The advent of prostate specific antigen (PSA) testing has lead to an increase in the number of men attending prostate assessment clinics. A substantial increase in incidence of prostate cancer (CaP) has been reported in U.K. []. CaP is now the commonest cancer in men, accounting for nearly 35,000 new cancer cases in the UK in 2004 and over 0,000 deaths in 2006 [2]. Diagnosis of early CaP comprises PSA * Corresponding author. Tel.: address: indianajoe@gmail.com (J. Philip). assay, digital rectal examination (DRE) and trans-rectal ultrasound (TRUS) guided biopsies. Traditionally, an elevated PSA level (>2.5 ng/ml) and/or an abnormal DRE necessitate a TRUS guided systematic biopsy for tissue diagnosis before initiating treatment. The use of PSA as a focal point in providing evidence that an individual man requires a prostatic biopsy for cancer detection is generally accepted [3]. Studies have shown complications in up to 60% of these patients [4,5]. Studies in our department have confirmed similar findings with over 80% of patients reporting transient haematuria, rectal bleeding or haematospermia and with 4% requiring hospitalisation [6]. Documented urinary tract infection rates were less than 3%. Naughton X/$ see front matter # 2008 Elsevier Ltd. All rights reserved. doi:0.06/j.cdp
2 J. Philip et al. / Cancer Detection and Prevention 32 (2009) et al. reported significantly greater rectal bleeding and haematospermia after increasing the number of cores taken [7]. Ghani et al. analysed the literature on prostate biopsy complications; reporting an increase in median haematuria rate from 39% to 7% when comparing six cores to more than eight cores [8]. Older men who attend for a biopsy show a haemophilic tendency with most of these men taking anticoagulants or antiplatelet drugs. In these men with high co-morbidity, complications trivial in younger men could become potentially life threatening. Limiting the number of prostate biopsies would be clinically advantageous in reducing potential and serious complications. We hypothesized that patients with markedly raised PSA values did not need extended prostate biopsy protocols. Cancer positive cores in men with PSA >0 ng/ml undergoing 2-core biopsy protocols were mapped in order to identify optimal limited biopsy protocols in these men. 2. Patients and methods Over a five-year period from 999 to 2004, 036 men attended the Urology Department s prostate assessment clinic with a raised PSA level (>2.5 ng/ml) and underwent a TRUS guided prostate biopsy. 436 patients had PSA levels >0 ng/ml and were included in this study. Biopsies were performed in a standardized manner using a BK Medical ultrasound machine with a 7.5 MHz trans-rectal ultrasound probe and an 8 gauge core biopsy needle with an Achieve spring loaded biopsy gun. A standard 2-core biopsy was employed throughout. Patients received 0 ml of % lignocaine peri-prostatic nerve block for local anaesthesia and antibiotic prophylaxis. The 2-core biopsy technique incorporates 6 laterally targeted biopsies in addition to the conventional para-sagittal sextant biopsies [9]. The peripheral biopsies were obtained by directing the needle towards the lateral aspect of the prostate for cores A F, from the base, mid-zone and apices (Fig. ). All patients underwent prostate biopsy according to protocol. All 2-core biopsy specimens were collected separately in prelabelled containers of 0% neutral buffered formalin. Histopathological analysis was performed on an individual core basis according to current histological practice [0,]. Men with PSA values >50 ng/ml had limited systematic biopsies. These patients had a minimum of six cores from the peripheral zones as described in the protocol and further cores (if taken) from the para-sagittal zones. The distribution of cancer detection patterns was assessed with the objective of stratifying biopsy protocols. Fig.. 2-core Prostate biopsy protocol. Key: (A) Right peripheral base; (B) Right peripheral mid-zone; (C) Right peripheral apex; (D) Left peripheral base; (E) Left peripheral mid-zone; (F) Left peripheral apex; (G) Right para-sagittal base; (H) Right para-sagittal mid-zone; (I) Right parasagittal apex; (J) Left para-sagittal base; (K) Left para-sagittal mid-zone; (L) Left para-sagittal apex. were diagnosed with cancer (62%) of whom 253 (58%) were diagnosed after the initial biopsy. Table explains the patient demographics and cancer detection rates for the different PSA levels. Clinical staging (DRE) and cancer detection rates are summarised in Fig. 2. Higher PSA levels and advanced clinical stage were associated with increased cancer detection rates. All clinical T3 and T4 patients had cancer diagnosed on biopsy. 58 of the 37 (42%) patients with normal DRE were diagnosed with CaP. Accuracy increased with PSA levels with positive predictive value increasing from 56% in patients with PSA 0 20 ng/ml, 85% for levels ng/ml and 93% in patients with PSA >50 ng/ml. 58 (82.3%) patients with PSA >20 ng/ml were diagnosed with CaP on biopsy (Table 2). Of these, all but two had Gleason scores of >5 with 32% having poorly 3. Results Mean age of the 436 men with PSA >0 ng/ml was 70.3 years (range: years, SD 7.8). In total, 270 patients Fig. 2. Clinical stage (DRE) and cancer detection rate.
3 36 J. Philip et al. / Cancer Detection and Prevention 32 (2009) Table Patient demographics and cancer detection rates. PSA range (n) Biopsy diagnosis (n) Mean age (range) (years) Median PSA (range) (ng/ml) ng/ml(244) Cancer detection rate = 46% ng/ml (9) Cancer detection rate = 76% >50 ng/ml (73) Cancer detection rate = 93% Malignant (2) Benign (32) Malignant (90) Benign (29) Malignant (68) Benign (5) 69. (43 83) 68. (47 89) 72. (53 87) 72.4 (60 85) 72.9 (49 90) 75 (6 90) 3.9 (0. 9.9) 2.7 (0. 9.9) 30.6 ( ) 25.8 ( ) 95.5 ( ) 03 ( ) Table 2 Biopsy characteristics of 58 prostate cancer patients with a PSA >20 ng/ml. PSA (ng/ml) Age in years Extent of disease % of cores involved Gleason score Previous biopsy < >80 One lobe Bi-lobar < >75 < Yes No > Table 3 Cancer detection rates for limited prostate biopsy templates >50 Peripheral and para-sagittal base and apex (8 cores) Periperhal base, apex and para-sagittal apex (6 cores) Peripheral base and apex (4 cores) Para-sagittal (6 cores) Para-sagittal base and apex (4 cores) 99% 78% 54% 48% 98% 42% 38% 89% 62% 62% differentiated CaP. 48% of men had more than six cores involved. 6% had bi-lobar disease. The percentage cancer detection rates for different biopsy protocols are in Table 3. Standard six-core biopsy protocol resulted in cancer detection rates of only 42 62%. Surprisingly, a four-core protocol with cores from peripheral bases and apices had higher CDR (78 98%). Additional two cores from the para-sagittal apex gave a CDR in men with PSA >20 ng/ml. All 2 cancers in men with PSA 0 20 ng/ml would have been detected with an eight-core biopsy protocol (Fig. 3) and the 58 men (PSA >20 ng/ml) with cancer would have had their diagnosis confirmed with a six-core biopsy protocol (Fig. 4). Fig. 3. Suggested 8-core biopsy protocol (PSA 0 20 ng/ml). Fig. 4. Suggested 6-core biopsy protocol (PSA >20 ng/ml).
4 J. Philip et al. / Cancer Detection and Prevention 32 (2009) Discussion The data reported in this paper supports the hypothesis that it is unnecessary to perform 2-core needle biopsy sampling of the prostate in men with a PSA level >0 ng/ ml in order to diagnose CaP. Programmes for the detection of CaP depend on PSA determination as a key criterion for biopsy; the specificity and sensitivity of this parameter is questionable [2]. A TRUS guided systematic prostate biopsy is required to obtain tissue for confirmatory histopathological diagnosis is therefore a necessity. Despite increased awareness of CaP, our study had 9% of the men attending the clinic with PSA levels more than 20 ng/ml. Most urology departments are offering men attending the prostate clinic extended and multiple biopsy protocols even in men with higher PSA levels. Prostate biopsy is accompanied by potentially significant morbidity as well as being an uncomfortable procedure [3]. Most studies report significant complications such as haematuria and rectal bleeding. Eichler et al. in their review had reported 80 82% haematuria and haemospermia rates with 2-core biopsies with a marked reduction in complication rates with reduced number of cores [4]. Ghani et al. also reported reduced rectal bleeding with reduction in cores [8]. We have mapped limited biopsy protocols to detect CaP in men with markedly raised (>0 ng/ml) PSA levels maintaining a cancer detection rates. The overall cancer detection rate in this current patient cohort was 43% in keeping with published data [5,6]. There was a proportional increased cancer detection rate with older men and higher PSA levels as well as in men with advanced clinical stage. The necessity of 0 2-core biopsy protocols to diagnose CaP in men with PSA levels below 0 ng/ml has been well elucidated [9,7 20]. Peripheral biopsies have been reported to increase cancer detection rates. [9,20,2]. However, the necessity for extended protocols in men with PSA levels of more than 20 ng/ml is debatable. Previous reports have only analysed cancer detection rates comparing sextant biopsy versus extended protocols [2]. Gerstenbluth et al. used a sextant plus additional lesion directed biopsies reporting cancer detection rates of 87% at cut off PSA of 20 ng/ml [22]. We report a cancer detection rate of 82% in this group which is lower but only 4% required a repeat biopsy. Our assessment clinic has most patients attending from the primary care with a single raised reading. We feel that adequate clinical assessment and at least one repeat PSA assay would reduce biopsy rates, even in men with PSA levels >20 ng/ml. Patients with high PSA values (>20 ng/ml) had undifferentiated tumours identified by an increased proportion of men with high Gleason scores (Table 3). They also had an elevated tumour volume with more men having bilobar disease and a greater number of positive cores. PPV for CaP was also very high in this group (82%+). Our attempt to map optimum biopsy protocols have been hampered by the variable number of cores undertaken in men with PSA >20 ng/ml. However, all these men had an initial set of peripheral biopsies and the variability was in the number of para-sagittal biopsies. Also, the variable sites of positive cores precluded standard limited biopsy protocols such as the sextant biopsy protocols. We have therefore mapped hybrid limited protocols maintaining CDR (Figs. 3 and 4) Patients with PSA levels between 0 20 ng/ml needed only 8 cores to diagnose CaP with the biopsy protocol to include the peripheral and para-sagittal basal and apical biopsies. In patients with PSA level of >20 ng/ml; a protocol of six cores to include the right and left peripheral basal and apical, and para-sagittal apical biopsies would give a CaP detection rate. 5. Conclusion Patients with PSA values > 20 ng/ml had a CDR of 82%. These men tend to have poorly differentiated tumours with a higher tumour volume. However, variable positive core sites require a limited but hybrid protocols to obtain maximum cancer yield. TRUS guided prostate biopsy in patients with PSA 0 20 ng/ml required only 8 cores to diagnose CaP. Patients with PSA >20 ng/ml would have had cancer diagnosed with a six-core biopsy concentrated on the apical region. We suggest limited biopsy protocols for men with PSA values >0 ng/ml. Conflict of interest None. Reference [] Rowan S, Rachet B, Alexe DM, Cooper N, Coleman MP. Survival from prostate cancer in England and Wales up to 200. Br J Cancer 2008; 99:S75 7. [2] CRUK_PDFs/prostate/CSPROSTATEKEYFACT08.pdf. [3] Guru K, Tewari A, Hemal AK, Wei J, Javidan J, Peabody J. The role of prostate specific antigen in screening and management of clinically localized prostate cancer. Int Urol Nephrol 2003; 35():07 3. [4] Rietbergen JB, Kruger AE, Kranse R, Schroder FH. Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening program. Urology 997; 49(6): [5] Djavan B, Waldert M, Zlotta A, Dobronski P, Seitz C, Remzi M. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: result of a prospective European prostate cancer detection study. J Urol 200; 66(3): [6] Ragavan N, Philip J, Balasubramanian SP, Desouza J, Marr C, Javle P. A randomised controlled trial comparing lignocaine peri-prostatic nerve block (PPNB), diclofenac suppository and both in transrectal ultrasound (TRUS) guided biopsy of prostate. J Urol 2005; 74(2):50 3. [7] Naughton CK, Ornstein DK, Smith DS, Catalona WJ. Pain and morbidity of transrectal ultrasound guided prostate biopsy: a pros-
5 38 J. Philip et al. / Cancer Detection and Prevention 32 (2009) pective randomized trial of 6 versus 2 cores. J Urol 2000; 63: [8] Ghani KR, Dundas D, Patel U. Bleeding after transrectal ultrasonography-guided prostate biopsy: a study of 7-day morbidity after a six-, eight- and 2-core biopsy protocol. BJU Int 2004; 94: [9] Philip J, Ragavan N, DeSouza J, Foster CS, Javlé P. Effect of peripheral biopsies in maximising early prostate cancer detection in 8-, 0- or 2-core biopsy regimes. BJU Int 2004; 93(9): [0] Bostick DG, Foster CS. Predictive factors in prostate cancer: current concepts from the 999 college of American Pathologists Conference on solid tumour prognostic factors and the 990 World Health Organization second international consultation on prostate cancer. Sem Urol Oncol 999; 7(4): [] Foster CS. Towards a consensus protocol on prostate biopsies: indications, techniques and assessment. Report of a Conference held at the Royal College of Pathologists, London 6th June Sponsored by the NHS Prostate Cancer Risk Management Programme. Organised by the Department of Pathology, University of Liverpool, UK. Sheffield UK: NHS Cancer Screening Programmes; 2006 [accessed 2008 Sep 7]. Available from [2] Steuber T, Helo P, Lilja H. Circulating biomarkers for prostate cancer. World J Urol 2007; 25(2): 9. [3] Desmond PM, Clark J, Thompson IM, Zeidman EJ, Mueller EJ. Morbidity with contemporary prostate biopsy. J Urol 993; 50(5 Pt ): [4] Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 2006; 75: [5] Presti Jr JC, Chang JJ, Bhargava V, Shinohara K. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsy cores: results of a prospective clinical trial. J Urol 2000; 63():63 7. [6] Gore JL, Shariat SF, Miles BJ, Kadmon D, Jiang N, Wheeler TM. Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol 200; 65(5): [7] Ravery V, Goldblatt L, Royer B, Blanc E, Toublanc M, Boccon-Gibod L. Extensive biopsy protocol improves the detection rate of prostate cancer. J Urol 2000; 64: [8] Terris MK, Wallen EM, Stamey TA. Comparison of mid-lobe versus lateral systematic sextant biopsies in the detection of prostate cancer. Urol Int 997; 59(4): [9] Levine MA, Ittman M, Melamed J, Lepor H. Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. J Urol 998; 59:47 5. [20] Presti Jr JC, O Dowd GJ, Miller MC, Mattu R, Veltri RW. Extended peripheral biopsy scheme increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: Results of a community multipractice study. J Urol 2003; 69:25 9. [2] Babaian RJ, Toi A, Kamoi K, Troncoso P, Sweet J, Evans R. A comparative analysis of sextant and an extended -core multisite directed biopsy strategy. J Urol 2000; 63:52 7. [22] Gerstenbluth RE, Seftel AD, Hampel N, Oefelein MG, Resnick MI. The accuracy of the increased prostate specific antigen level (greater than or equal to 20 ng/ml.) in predicting prostate cancer: is biopsy always required? J Urol 2002; 68:990 3.
ONCOLOGY LETTERS 8: , 2014
1834 Systematic 12 and 13 core transrectal ultrasound or magnetic resonance imaging guided biopsies significantly improve prostate cancer detection rate: A single center 13 year experience GONG CHENG *,
More informationUltrasound-guided transrectal extended prostate biopsy: a prospective study
DOI: 10.1111/j.1745-7262.2005.00019.x. Original Article. Ultrasound-guided transrectal extended prostate biopsy: a prospective study Mohammed Ahmed Al-Ghazo, Ibrahim Fathi Ghalayini, Ismail Ibrahim Matalka
More informationFisher s exact test for contingency tables. A two-tailed p-value <0.05 was accepted as statistically significant.
BJUI A prospective, randomized trial comparing the Vienna nomogram to an eight-core prostate biopsy protocol Angus Lecuona and Chris F. Heyns Department of Urology, Tygerberg Hospital and University of
More informationIndividualized prostate biopsy strategy for Chinese patients with different prostate-specific antigen levels
DOI: 10.1111/j.1745-7262.2008.00345.x www.asiaandro.com. Clinical Experience. Individualized prostate biopsy strategy for Chinese patients with different prostate-specific antigen levels Bo Dai 1,4, Ding-Wei
More informationComputer simulated additional deep apical biopsy enhances cancer detection in palpably benign prostate gland
Blackwell Publishing AsiaMelbourne, AustraliaIJUInternational Journal of Urology0919-81722006 Blackwell Publishing Asia Pty Ltd? 200613?12901295Original ArticleAdditional apical biopsy in prostatic gland
More informationBJUI. Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer
2008 The Authors. Journal compilation 2008 BJU International Original Article TEMPLATE-BASED PROSTATE BIOPSY SYSTEM MEGWALU et al. BJUI BJU INTERNATIONAL Evaluation of a novel precision template-guided
More informationCancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject:
Subject: Saturation Biopsy for Diagnosis, Last Review Status/Date: September 2016 Page: 1 of 9 Saturation Biopsy for Diagnosis, Description Saturation biopsy of the prostate, in which more cores are obtained
More informationor more transrectal ultrasonography (TRUS)-guided ng/ml and 39% if it was 20.0 ng/ml. of >10 ng/ml have prostate cancer [3], many other
BJU International (1999), 83, 34 38 Elevated serum prostate specific antigen levels in conjunction with an initial prostatic biopsy negative for carcinoma: who should undergo a repeat biopsy? G.C. DURKAN
More informationTransrectal ultrasound-guided biopsy for the diagnosis of prostate cancer
Transrectal ultrasound-guided for the diagnosis of prostate cancer Adrian Haşegan Clinica de Urologie, Spitalul Clinic Judeţean de Urgenţă Sibiu Facultatea de Medicină Sibiu Abstract Transrectal ultrasound-guided
More informationAre extended biopsies really necessary to improve prostate cancer detection?
(2003) 6, 250 255 & 2003 Nature Publishing Group All rights reserved 1365-7852/03 $25.00 www.nature.com/pcan Are extended biopsies really necessary to improve prostate cancer detection? R Damiano*,1, R
More informationExtended 12-Core Prostate Biopsy Increases Both the Detection of Prostate Cancer and the Accuracy of Gleason Score
european urology xxx (2005) xxx xxx available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Extended 12-Core Prostate Biopsy Increases Both the Detection of Prostate
More informationProstate gold seed fiducial implantation by radiation oncologists: A report on feasibility
Prostate gold seed fiducial implantation by radiation oncologists: A report on feasibility Poster No.: R-0006 Congress: Type: Authors: Keywords: DOI: 2014 CSM Scientific Exhibit C. Jayaratne, A. Brown,
More informationGetting to Diagnosis. Debbie Victor Uro-Oncology CNS Royal Cornwall Hospitals Trust
Getting to Diagnosis Debbie Victor Uro-Oncology CNS Royal Cornwall Hospitals Trust GP Visit Symptoms Reduced urinary flow Difficulty starting/stopping Urgency Frequency Nocturia Because a friend/relative
More informationRole of Prostate-Specific Antigen Change Ratio at Initial Biopsy as a Novel Decision-Making Marker for Repeat Prostate Biopsy
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53..46 Urological Oncology Role of Prostate-Specific Antigen Change Ratio at Initial Biopsy as a Novel Decision-Making Marker for Repeat Prostate Biopsy
More informationConclusion: PPNB with one percent lignocaine. is a safe analgesic procedure to perform in
Original Article Singapore Med J 2011, 52(10) 752 Incidence of complications after transrectal ultrasonography-guided biopsy of the prostate in a local tertiary institution Wu M W F, Sevilla E M, Raman
More informationThe Chances of Subsequent Cancer Detection in Patients with a PSA > 20 ng/ml and an Initial Negative Biopsy
Research Article TheScientificWorldJOURNAL (2009) 9, 343 348 TSW Urology ISSN 1537-744X; DOI 10.1100/tsw.2009.47 The Chances of Subsequent Cancer Detection in Patients with a PSA > 20 ng/ml and an Initial
More informationCorporate Medical Policy
Corporate Medical Policy Saturation Biopsy for Diagnosis, Staging, and Management of Prostate File Name: Origination: Last CAP Review: Next CAP Review: Last Review: saturation_biopsy_for_diagnosis_ staging_and_management_of_prostate_cancer
More informationTHE SIGNIFICANCE OF HYPOECHOIC LESION DIRECTED AND TRANSITION ZONE BIOPSIES IN IMPROVING THE DIAGNOSTIC ABILITY IN PROSTATE CANCER
Clinical Urology Brazilian Journal of Urology Official Journal of the Brazilian Society of Urology Vol. 27 (3): 222-226, May - June, 2001 THE SIGNIFICANCE OF HYPOECHOIC LESION DIRECTED AND TRANSITION ZONE
More informationIs Prostate Biopsy Essential to Diagnose Prostate Cancer in the Older Patient with Extremely High Prostate-Specific Antigen?
www.kjurology.org http://dx.doi.org/1.4111/kju.1.3..8 Urological Oncology Is Prostate Biopsy Essential to Diagnose Prostate Cancer in the Older Patient with Extremely High Prostate-Specific Antigen? Jee
More informationTWELVE CORE PROSTATE BIOPSY VERSUS SIX SYSTEMATIC SEXTANT BIOPSIES
Clinical Urology Brazilian Journal of Urology Vol. 28 (3): 207-213, May - June, 2002 Official Journal of the Brazilian Society of Urology TWELVE CORE PROSTATE BIOPSY VERSUS SI SYSTEMATIC SETANT BIOPSIES
More informationProspective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort
European Journal of Cancer (2012) 48, 1809 1815 Available at www.sciencedirect.com journal homepage: www.ejconline.com Prospective validation of a risk calculator which calculates the probability of a
More informationSaturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer
Saturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer Policy Number: 7.01.121 Last Review: 2/2018 Origination: 8/2006 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationDoes a New Ultrasound Probe Change the Complication Rates of Transrectal Ultrasound-guided Needle Biopsies of the Prostate?
Does a New Ultrasound Probe Change the Complication Rates of Transrectal Ultrasound-guided Needle Biopsies of the Prostate? THORSTEN H. ECKE 1, HOLGER GERULLIS 2,3, CHRISTOPH J. HEUCK 4, PETER BARTEL 1,
More informationSaturation Biopsy for Diagnosis, Staging, and Management of Prostate Cancer
Saturation Biopsy for Diagnosis, Staging, and Management of Prostate Cancer Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana,
More informationOriginal Article Optimization of prostate cancer diagnosis by increasing the number of core biopsies based on gland volume
Int J Clin Exp Pathol 2012;5(9):892-899 www.ijcep.com /ISSN:1936-2625/IJCEP1207013 Original Article Optimization of prostate cancer diagnosis by increasing the number of core biopsies based on gland volume
More informationSaturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer
Saturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer Policy Number: 7.01.121 Last Review: 2/2019 Origination: 8/2006 Next Review: 8/2019 Policy Blue Cross and Blue Shield of Kansas
More informationContribution of prostate-specific antigen density in the prediction of prostate cancer: Does prostate volume matter?
ORIGINAL ARTICLE Gulhane Med J 2018;60: 14-18 Gülhane Faculty of Medicine 2018 doi: 10.26657/gulhane.00010 Contribution of prostate-specific antigen density in the prediction of prostate cancer: Does prostate
More informationOwing to the widespread use of prostate specific antigen (PSA)
ORIGINAL RESEARCH Subsequent prostate cancer detection in patients with prostatic intraepithelial neoplasia or atypical small acinar proliferation Moamen M. Amin, MD; Suganthiny Jeyaganth, MSc; Nader Fahmy,
More informationJMSCR Vol 05 Issue 03 Page March 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i3.135 Diagnosis of Carcinoma Prostate Based
More informationBJUI. Follow-up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer?
. JOURNAL COMPILATION 2010 BJU INTERNATIONAL Urological Oncology FOLLOW-UP OF MEN WITH AN ELEVATED PCA3 SCORE AND A NEGATIVE BIOPSY REMZI ET AL. BJUI BJU INTERNATIONAL Follow-up of men with an elevated
More informationMRI in the Enhanced Detection of Prostate Cancer: What Urologists Need to Know
MRI in the Enhanced Detection of Prostate Cancer: What Urologists Need to Know Michael S. Cookson, MD, FACS Professor and Chair Department of Urology Director of Prostate and Urologic Oncology University
More informationInpyeong Hwang, Sang Youn Kim, Jeong Yeon Cho, Myoung Seok Lee, Seung Hyup Kim
The diagnostic ability of an additional midline peripheral zone biopsy in transrectal ultrasonography-guided 12-core prostate biopsy to detect midline prostate cancer Inpyeong Hwang, Sang Youn Kim, Jeong
More informationProstate-Specific Antigen (PSA) Test
Prostate-Specific Antigen (PSA) Test What is the PSA test? Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationMajor Complications and Associated Risk Factors of Transrectal Ultrasound Guided Prostate Needle Biopsy: A Retrospective Study of 1875 Cases in Taiwan
ORIGINAL ARTICLE Major Complications and Associated Risk Factors of Transrectal Ultrasound Guided Prostate Needle Biopsy: A Retrospective Study of 1875 Cases in Taiwan I-Ni Chiang, 1 Shang-Jen Chang, 2
More informationControversies in Prostate Cancer Screening
Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations
More informationEfficacy of Pelvic Diffusion Weighted MRI Prior to Prostate Biopsy in Patients with tpsa Level of 2,5-20 ng/ml for Determination of Malign Lesions
ISPUB.COM The Internet Journal of Urology Volume 14 Number 1 Efficacy of Pelvic Diffusion Weighted MRI Prior to Prostate Biopsy in Patients with tpsa Level of 2,5-20 ng/ml for Determination of Malign Lesions
More informationHow to detect and investigate Prostate Cancer before TRT
How to detect and investigate Prostate Cancer before TRT Frans M.J. Debruyne Professor of Urology Andros Men s Health Institutes, The Netherlands Bruges, 25-26 September 2014 PRISM Recommendations for
More informationKey Words: Aged; Biopsy; Magnetic resonance imaging; Prostatic neoplasms; Prostate-specific antigen
pissn: 2287-4208 / eissn: 2287-4690 World J Mens Health 2015 December 33(3): 188-193 http://dx.doi.org/10.5534/wjmh.2015.33.3.188 Original Article The Practicality of Targeted Prostate Biopsy Procedures
More informationThe In uence of Prostate Volume on Prostate Cancer Detection
European Urology Supplements European Urology Supplements 1 (2002) 35±39 The In uence of Prostate Volume on Prostate Cancer Detection Michael K. Brawer * Northwest Prostate Institute, Seattle, USA Abstract
More informationTRANSRECTAL ULTRASOUND-GUIDED PROSTATE BIOPSY, PERIPROSTATIC LOCAL ANESTHESIA AND PAIN TOLERANCE
& TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BIOPSY, PERIPROSTATIC LOCAL ANESTHESIA AND PAIN TOLERANCE Mustafa Hiroš 1 *, Mirsad Selimović 1, Hajrudin Spahović 1, Sabina Sadović 1, Ediba Spužić-Čelić 2 1 Urology
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationProstate Biopsy in 2017
Prostate Biopsy in 2017 Bob Djavan, MD, PhD Professor and Chairman, Department of Urology, Rudolfinerhaus Foundation Hospital,Vienna, Austria Director Vienna Urology foundation Board member Scientific
More informationUrological Society of Australia and New Zealand PSA Testing Policy 2009
Executive summary Urological Society of Australia and New Zealand PSA Testing Policy 2009 1. Prostate cancer is a major health problem and is the second leading cause of male cancer deaths in Australia
More informationScreening for Prostate Cancer
Screening for Prostate Cancer Review against programme appraisal criteria for the UK National Screening Committee (UK NSC) Version 1: This document summarises the work of ScHARR 1 2 and places it against
More informationWhat Is the Ideal Core Number for Ultrasound-Guided Prostate Biopsy?
www.kjurology.org http://dx.doi.org/1.4111/kju.214.55.11.725 Original Article - Urological Oncology http://crossmark.crossref.org/dialog/?doi=1.4111/kju.214.55.11.725&domain=pdf&date_stamp=214-11-16 What
More informationIntroduction. Key Words: high-grade prostatic intraepithelial neoplasia, HGPIN, radical prostatectomy, prostate biopsy, insignificant prostate cancer
Prostate cancer after initial high-grade prostatic intraepithelial neoplasia and benign prostate biopsy Premal Patel, MD, 1 Jasmir G. Nayak, MD, 1,2 Zlatica Biljetina, MD, 4 Bryan Donnelly, MD 3, Kiril
More informationHistopathological Study of Transrectal Ultrasound Guided Biopsies of Prostate
ORIGINAL ARTICLE Histopathological Study of Transrectal Ultrasound Guided Biopsies of Prostate in Patients With Raised Serum Prostate Specific Antigen Prabha Rathour 1, Hetal Jani 2, Urvi Parikh 3, Hansa
More informationDetection of prostate cancer by MR-ultrasound fusion guided biopsy
Detection of prostate cancer by MR-ultrasound fusion guided biopsy Poster No.: C-0761 Congress: ECR 2014 Type: Scientific Exhibit Authors: T. Durmus, C. Stephan, T. Slowinski, A. Thomas, A. Maxeiner, B.
More informationThe utility of transrectal sonoelastography in preoperative prostate cancer assessment
Original papers Medical Ultrasonography 2012, Vol. 14, no. 3, 182-186 The utility of transrectal sonoelastography in preoperative prostate cancer assessment Steffen Rausch 1, Wibke Alt 2, Hartmut Arps
More informationDoes normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy?
Original Article Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy? Sherif Azab 1, Ayman Osama 2, Mona Rafaat 3 1 Urology Department, Faculty
More informationPREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS
ADULT UROLOGY PREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS ABRAHAM MORGENTALER AND ERNANI LUIS RHODEN ABSTRACT Objectives. To determine
More informationINTEROBSERVER VARIATION OF PROSTATIC VOLUME ESTIMATION WITH DIGITAL RECTAL EXAMINATION BY UROLOGICAL STAFFS WITH DIFFERENT EXPERIENCES
Clinical Urology International Braz J Urol Official Journal of the Brazilian Society of Urology DIGITAL RECTAL EXAMINATION BY UROLOGICAL STAFFS Vol. 30 (6): 466-471, November - December, 2004 INTEROBSERVER
More informationPerformance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting
ORIGINAL ARTICLE (2010) 13, 71 77 & 2010 Nature Publishing Group All rights reserved 1365-7852/10 $32.00 www.nature.com/pcan Performance of transperineal template-guided mapping biopsy in detecting prostate
More informationProstate Cancer Detection and High Grade PIN
Clinical Urology Prostate Cancer Detection and High Grade PIN International Braz J Urol Vol. 37 (1): 87-93, January - February, 2011 doi: 10.1590/S1677-55382011000700011 The Implication of Initial 24-Core
More informationThe Impact of MRI-TRUS Cognitively Targeted Biopsy on the Incidence of Pathologic Upgrading After Radical Prostatectomy
Original Article World J Nephrol Urol. 2018;7(1):12-16 The Impact of MRI-TRUS Cognitively Targeted Biopsy on the Incidence of Pathologic Upgrading After Radical Prostatectomy Ragheed Saoud a, Albert El-Haj
More information, De La Taille Alexandre * INSERM : U955, Universit é Paris XII Val de Marne, IFR10, FR. , Universit é Paris XII Val de Marne, Créteil,FR
High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation on initial 21-core extended biopsy scheme: incidence and implications for patient care and surveillance Ploussard
More informationThe Role of TURP in the Detection of Prostate Cancer in BPH Patients with Previously Negative Prostate Biopsy
www.kjurology.org DOI:10.4111/kju.2010.51.5.313 Urological Oncology The Role of TURP in the Detection of Prostate Cancer in BPH Patients with Previously Negative Prostate Biopsy Dae Keun Kim, Sang Jin
More informationOriginal Paper. Urol Int 2013;90: DOI: /
Urologia Internationalis Original Paper Received: January 27, 2012 Accepted after revision: November 26, 2012 Published online: February 13, 2013 Comparison of Transrectal Prostate Biopsy Results with
More informationTHE UROLOGY GROUP
THE UROLOGY GROUP www.urologygroupvirginia.com 1860 Town Center Drive Suite 150/160 Reston, VA 20190 703-480-0220 19415 Deerfield Avenue Suite 112 Leesburg, VA 20176 703-724-1195 224-D Cornwall Street,
More informationPost Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series
Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,
More informationProstate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144
Prostate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144 Objectives: Detection of prostate cancer the need for better imaging What
More informationof Nebraska - Lincoln
University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln U.S. Department of Veterans Affairs Staff Publications U.S. Department of Veterans Affairs 8-2000 Detection, Characterization,
More informationRepeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA?
Repeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA? Connolly, D., Black, A., Murray, L., Nambirajan, T., Keane, P. F., & Gavin, A. (2009). Repeating an abnormal
More informationProstate Biopsy Michael Holmes. FRACS (Urology)
Prostate Biopsy Michael Holmes FRACS (Urology) Why have a Prostate biopsy? A prostate biopsy will have been recommended if your PSA. was elevated The rectal examination was abnormal or wrong The PSA is
More informationCorrelation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer
ORIGINAL ARTICLE Correlation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer Teng-Fu Hsieh, Chao-Hsian Chang, Wen-Chi Chen, Chien-Lung
More informationPrognostic Value of Surgical Margin Status for Biochemical Recurrence Following Radical Prostatectomy
Original Article Japanese Journal of Clinical Oncology Advance Access published January 17, 2008 Jpn J Clin Oncol doi:10.1093/jjco/hym135 Prognostic Value of Surgical Margin Status for Biochemical Recurrence
More informationThe TRUS guided prostate extended biopsy in the detection of prostate cancer
Mædica - a Journal of Clinical Medicine ORIGIN RIGINAL PAPERS The TRUS guided prostate extended biopsy in the detection of prostate cancer Assoc. Prof. V. AMBERT, MD, PhD; A. ATEIA, MD; I. CHIRA, MD, PhD;
More informationEUROPEAN UROLOGY 58 (2010)
EUROPEAN UROLOGY 58 (2010) 551 558 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Prostate Cancer Prevention Trial and European Randomized Study of Screening
More informationFocus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer
Focus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer Prostate Cancer in Ireland & Worldwide In Ireland, prostate cancer
More informationProstate cancer smart screening, precision diagnosis, personalised treatment'
Prostate cancer smart screening, precision diagnosis, personalised treatment' Prof. Hashim Ahmed PhD, FRCS(Urol), BM, BCh (Oxon), BA(Hons) Consultant Urological Surgeon Bupa Cromwell Hospital Clinics:
More informationDIAGNOSIS OF NONSPECIFIC GRANULOMATOUS PROSTATITIS IN PATIENTS UNDERGOING PROSTATE BIOPSY UNDER TRANSRECTAL ULTRASOUND GUIDANCE
32, 4, 2010, 3.,.. DIAGNOSIS OF NONSPECIFIC GRANULOMATOUS PROSTATITIS IN PATIENTS UNDERGOING PROSTATE BIOPSY UNDER TRANSRECTAL ULTRASOUND GUIDANCE N. Smilov, N. Koleva and I. Lozev Medical Institute Ministry
More informationSignificance of Atypical Small Acinar Proliferation and High-Grade Prostatic Intraepithelial Neoplasia in Prostate Biopsy
www.kjurology.org http://dx.doi.org/1.4111/kju.211.52.11.736 Urological Oncology Significance of Atypical Small Acinar Proliferation and HighGrade Prostatic Intraepithelial Neoplasia in Prostate Biopsy
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More information10/2/2018 OBJECTIVES PROSTATE HEALTH BACKGROUND THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION
THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION Lenette Walters, MS, MT(ASCP) Medical Affairs Manager Beckman Coulter, Inc. *phi is a calculation using the values from PSA, fpsa and p2psa
More informationSubject: Prostate Saturation Biopsy
02-54000-22 Original Effective Date: 01/01/10 Reviewed: 09/27/18 Revised: 10/15/18 Subject: Prostate Saturation Biopsy THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationMR-US Fusion Guided Biopsy: Is it fulfilling expectations?
MR-US Fusion Guided Biopsy: Is it fulfilling expectations? Kenneth L. Gage MD, PhD Assistant Member Department of Diagnostic Imaging and Interventional Radiology 4 th Annual New Frontiers in Urologic Oncology
More informationThuchchai Pipitpanpipit, M.D.
ARC Journal of Urology Volume 1, Issue 2, 2016, PP 15-19 www.arcjournals.org Prospective Randomized Controlled Study of the Results of Medication with Oral versus Oralcefixime to Prevent Transient Bacteraemia
More informationDeveloping a new score system for patients with PSA ranging from 4 to 20 ng/ ml to improve the accuracy of PCa detection
DOI 10.1186/s40064-016-3176-3 RESEARCH Open Access Developing a new score system for patients with PSA ranging from 4 to 20 ng/ ml to improve the accuracy of PCa detection Yuxiao Zheng, Yuan Huang, Gong
More informationEfficacy of Serum Prostate Specific Antigen (PSA), Digital Rectal Examination (DRE)
ORIGINAL ARTICLE Efficacy of Serum Prostate Specific Antigen (PSA), Digital Rectal Examination (DRE) and 12-core Transrectal ultrasound (TRUS) guided biopsy in detecting Carcinoma Prostate B. Vijayalakshmi
More informationA schematic of the rectal probe in contact with the prostate is show in this diagram.
Hello. My name is William Osai. I am a nurse practitioner in the GU Medical Oncology Department at The University of Texas MD Anderson Cancer Center in Houston. Today s presentation is Part 2 of the Overview
More information. ORIGINAL ARTICLES SERUM PROSTATE-SPECIFIC ANTIGEN AS SURROGATE FOR THE HISTOLOGICAL DIAGNOSIS OF PROSTATE CANCER
. SERUM PROSTATE-SPECIFIC ANTIGEN AS SURROGATE FOR THE HISTOLOGICAL DIAGNOSIS OF PROSTATE CANCER C F Heyns, AM Naude, G Ahmed, H B Stopforth, G A Stellmacher, A J Visser Introduction. To determine whether
More informationBJUI. Clinical staging error in prostate cancer: localization and relevance of undetected tumour areas
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology CLINICAL STAGING ERROR IN PROSTATE CANCER BOLENZ et al. BJUI BJU INTERNATIONAL Clinical staging error in prostate cancer: localization and
More informationThe Royal Marsden. Prostate case study. Presented by Mr Alan Thompson Consultant Urological Surgeon
Prostate case study Presented by Mr Alan Thompson Consultant Urological Surgeon 2 Part one Initial presentation A 62 year old male solicitor attends your GP surgery. He has rarely seen you over the last
More informationProstate Cancer Screening Guidelines in 2017
Prostate Cancer Screening Guidelines in 2017 Pocharapong Jenjitranant, M.D. Division of Urology, Department of Surgery, Faculty of Medicine, Ramathibodi Hospital Prostate Specific Antigen (PSA) Prostate
More informationMAKE REPEAT PROSTATE BIOPSY DECISIONS WITH CONFIDENCE. The Progensa PCA3 test
MAKE REPEAT PROSTATE BIOPSY DECISIONS WITH CONFIDENCE The Progensa PCA3 test is the first FDA-approved prostate cancer-specific test of its kind that gives you the information you need to determine if
More informationNomogram using transrectal ultrasound-derived information predicting the detection of high grade prostate cancer on initial biopsy
Original Article Prostate Int 2013;1(2):69-75 P R O S T A T E INTERNATIONAL Nomogram using transrectal ultrasound-derived information predicting the detection of high grade prostate cancer on initial biopsy
More informationAsian J Androl 2005; 7 (2): DOI: /j x
Asian J Androl 5; 7 (2): 159 163 DOI: 1.1111/j.1745-7262.5.29.x. Original Article. Mass screening of prostate cancer in a Chinese population: the relationship between pathological features of prostate
More informationSingle Positive Core Prostate Cancer in a 12-Core Transrectal Biopsy Scheme: Clinicopathological Implications Compared with Multifocal Counterpart
www.kjurology.org DOI:10.4111/kju.2010.51.10.671 Urological Oncology Single Positive Core Prostate Cancer in a 12-Core Transrectal Biopsy Scheme: Clinicopathological Implications Compared with Multifocal
More informationPCa Commentary. Executive Summary: The "PCa risk increased directly with increasing phi values."
1101 Madison Street Suite 1101 Seattle, WA 98104 P 206-215-2490 www.seattleprostate.com PCa Commentary Volume 77 September October 2012 CONTENT Page The Prostate 1 Health Index Active Surveillance 2 A
More informationeuropean urology 55 (2009)
european urology 55 (2009) 385 393 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Is Prostate-Specific Antigen Velocity Selective for Clinically Significant
More informationA biopsy can be avoided in patients with positive DRE and negative MRI. Disagree: Michael Cohen, Chairman, Dept. of Urol. Haemek M.
A biopsy can be avoided in patients with positive DRE and negative MRI Disagree: Michael Cohen, Chairman, Dept. of Urol. Haemek M.C, Afula, Israel Financial and Other Disclosures Off-label use of drugs,
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationProstate Cancer Local or distant recurrence?
Prostate Cancer Local or distant recurrence? Diagnostic flowchart Vanessa Vilas Boas Urologist VFX Hospital FEBU PSA - only recurrence PSA recurrence: 27-53% of all patients undergoing treatment with curative
More informationBJUI. Study Type Prognosis (individual cohort study) Level of Evidence 2b OBJECTIVES CONCLUSIONS
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTING THE OUTCOME OF PROSTATE BIOPSY HERNANDEZ et al. BJUI BJU INTERNATIONAL Predicting the outcome of prostate biopsy: comparison
More informationeuropean urology 54 (2008)
european urology 54 (2008) 1354 1362 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Evaluation of Prostate Cancer Detection with Ultrasound Real-Time Elastography:
More informationMRI-targeted, transrectal ultrasound-guided prostate biopsy for suspected prostate malignancy: A pictorial review
MRI-targeted, transrectal ultrasound-guided prostate biopsy for suspected prostate malignancy: A pictorial review Poster No.: C-1208 Congress: ECR 2014 Type: Educational Exhibit Authors: J. Murphy, M.
More informationDiagnostic TRUS Elastography of the Prostate
Diagnostic TRUS Elastography of the Prostate George Zacharopoulos Department of Diagnostic Ultrasound Hygeia Hospital Athens, Greece Prostate HI-RTE Why we need Elastography Better Detection of possible
More informationPSA and the Future. Axel Heidenreich, Department of Urology
PSA and the Future Axel Heidenreich, Department of Urology PSA and Prostate Cancer EAU Guideline 2011 PSA is a continuous variable PSA value (ng/ml) risk of PCa, % 0 0.5 6.6 0.6 1 10.1 1.1 2 17.0 2.1 3
More information